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Abstract: The endothelial lining of the blood-brain barrier tightly controls the distribution of 
peptide hormones between the central nervous system and the circulation.  Using primary 
cultures of brain microvessel endothelial cells, an in vitro model of the blood-brain barrier,  we 
report here the uptake and transport of the octapeptide angiotensin II by a specific receptor 
population.  Using the angiotensin II antagonists losartan (AT1 specific) and PD 123,319 (AT2 
specific) we have shown that both the uptake and transport of angiotensin II were mediated by 
the AT1 receptor.  Western blot analysis confirmed the existence of the AT1 receptor in our cell 
culture model.  Rhodamine 123 studies also suggested that both angiotensin II antagonists, but 
not angiotensin II, were substrates for the P-glycoprotein efflux system thus restricting the 
transport of these compounds.  These results suggest an AT1 receptor mediates uptake and 
transport of angiotensin II at the blood-brain barrier and may contribute to the regulation of 
cerebrovascular levels of the peptide. 
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Introduction 
The octapeptide angiotensin II produces a number of physiological actions, the most common 
of these being its peripheral role as a potent vasoconstrictor (1).  The renin angiotensin system 
is also known to exist in the brain (1-3).  Brain angiotensin II appears to function in the central 
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regulation of blood pressure, the regulation of body fluid volume, and the control of hormone 
release (4).  Angiotensin II does not readily penetrate the blood-brain barrier (BBB) and the 
effects of angiotensin II are generally considered to be mediated by receptors in the 
circumventricular regions of the brain which lack the BBB. 
Speth and Harik (5) and Grammas et al. (6) observed that there were angiotensin II receptor 
binding sites on the brain microvessel endothelial cells (BMECs) lining the BBB and that these 
binding sites have biological activity (7,8).  Subsequently, studies by Guillot and Audus reported 
that there were specific angiotensin II binding sites on BMECs in primary culture and that the 
cells internalized the peptide (9).  Angiotensin II receptors are also found on peripheral vascular 
endothelial cells and mediate transendothelial transport of the peptide (10).  The subtyping of 
these binding sites, however, has not been reported. 
There are two major subtypes of angiotensin II receptors known to exist, designated AT1 and 
AT2.  Both receptor subtypes have been found in brain tissue of rats, monkeys, and humans.  
Most of the known actions of angiotensin II are mediated through the AT1 receptor (11).  The 
development of nonpeptide antagonists has made it possible to distinguish between the two 
receptor subtypes.  Losartan is a highly specific nonpeptide AT1 antagonist and PD 123,319 is a 
highly specific nonpeptide AT2 antagonist.  These antagonists lack the partial agonist activities 
of peptide angiotensin II analogs, allowing study of angiotensin II processing without interfering 
side effects (11). 
The objective of this study was to use primary cultures of BMECs to reveal the receptor subtype 
populations that regulate angiotensin II uptake and distribution across the BBB.  The 
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nonpeptide antagonists losartan and PD 123,319 were used in this study to distinguish the AT1 
and AT2 receptor subtypes on BMECs.  The definition of receptor subtypes providing for the 
clearance of peptides at the BBB contributes to our knowledge of fundamental physiological 
mechanisms regulating cerebrovascular levels of vasoeffectors.  In addition, characterization of 
BBB carrier mechanisms potentially can provide physiological strategies to beneficially 
circumvent this barrier by covalently linking pharmacophores to receptor ligands known to be 
transported across the barrier (12). 
 
Materials and methods 
Materials 
[3H]-angiotensin II (specific activity 45 Ci/mmol) was purchased from Amersham (Arlington 
Heights, IL).   Losartan was donated by Merck & Co. (Rahway, NJ) and PD 123,319 
ditrifluoroacetate was purchased from Research Biochemicals International (Natick, MA).  
Cyclosporin A was purchased from Sigma Chemical Company (St. Louis, MO).  The AT1 (N-10) 
rabbit polyclonal antibody was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).  
All other compounds used were of the highest commercially available quality. 
Cell Culture 
Bovine brain microvessel endothelial cells (BMECs) were isolated from gray matter of cerebral 
cortices by enzymatic digestion and subsequent centrifugation, and seeded into primary culture 
as detailed by Audus and Borchardt (13,14).  This preparation has been extensively 
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characterized as reported in the literature (13,15-18).  Isolated BMECs were seeded at a density 
of 50,000 cells/cm2 into 12-well plates and 100 mm tissue culture dishes (Corning Costar 
Corporation, Cambridge, MA), pretreated with rat-tail collagen and bovine fibronectin (Sigma 
Chemical Co.) in a culture medium consisting of 45 % minimum essential medium, 45 % F-12 
Ham nutrient mixture (Gibco Life Technologies, Grand Island, NY), 10 mM HEPES, pH 7.4, 13 
mM sodium bicarbonate, 10 % plasma-derived equine serum, 100 µg/ml heparin, 100 µg/ml 
streptomycin, 100 µg/ml penicillin G, 50 µg/ml polymyxin B, and 2.5 µg/ml amphotericin B 
(Sigma Chemical Co.).  The cells were cultured at 37°C with 95 % humidity and 5 % CO2.  Cells 
were fed on the third day after seeding and then every two days until confluent monolayers 
were formed (10-14 days). 
Binding and internalization studies 
The effect of the nonpeptide antagonists on [3H]-angiotensin II binding and internalization was 
studied in 12-well plates at 37°C.  Aliquots of specified concentrations of losartan and PD 
123,319 dissolved in culture medium, containing equine serum, were added to each well with a 
pulse of [3H]-angiotensin II.  The plates were incubated for 30 minutes at 37°C.  At the 
conclusion of the experiment, the medium was aspirated from each well and the wells were 
rinsed three times with ice cold culture medium.  The cell monolayers were then solubilized by 
the addition of 1.0 ml of 0.2 N NaOH / 0.5 % Triton X-100.  An aliquot of 100 µl was removed to 
analyze protein content using the BCA protein assay kit (Pierce, Rockford, IL).  The remaining 
lysate from each well was collected, placed in a scintillation vial with 10 ml of scintillation 
cocktail, and assayed with a Beckman LS 6800 scintillation counter. 
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Rhodamine 123 uptake studies were also performed on confluent monolayers in 12-well plates.  
Angiotensin II, losartan, PD 123,319, or cyclosporin A dissolved in culture medium was added to 
each well and the plate was preincubated for one hour at 37°C.  After the one hour 
preincubation, rhodamine 123 was added to each well for a final concentration of 5 µM, and 
the plate was incubated at 37°C for an additional hour.  After the second incubation, the plate 
was rinsed and the monolayers were solubilized as described above.  The contents of each well 
were collected into cuvettes and assayed by fluorescence using an SLM-Aminco 4800 
fluorometer (ex = 500 nm, em = 550 nm).  After measuring relative fluorescence, 100 µl was 
removed from each cuvette and assayed for protein content with the BCA protein assay kit 
(Pierce). 
Transendothelial permeability studies 
Polycarbonate membranes (pore size 0.4 µm) were placed into 100 mm tissue culture dishes 
and coated with rat-tail collagen and bovine fibronectin.  BMECs were grown to confluent 
monolayers as determined by inspection of the areas around the membranes using an inverted 
microscope.  The basolateral side of the cells was defined as the side facing the collagen matrix.  
Once confluent monolayers were formed, the membranes were carefully placed into a 
horizontal Side-bi-Side diffusion apparatus (Crown Glass, Inc., Somerville, NJ) for 
transendothelial permeability studies.  The area of the diffusion membrane was 0.636 cm2.  The 
donor and receiver chambers were filled with 3.0 ml culture medium, containing equine serum, 
and the temperature was maintained at 37°C with an external circulating water bath.  The 
contents of each chamber were stirred with Teflon coated magnetic stir bars at a speed of 600 
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r/min driven by an external drive console (Crown Glass, Inc.).  The apical to basolateral 
transport of a pulse of [3H]-angiotensin II was studied for 30 minutes.  An aliquot of 25 µl was 
removed from the donor chamber to be assayed for initial donor concentration.  Sample 
aliquots of 100 µl were removed from the receiver chamber at various intervals.  Following the 
30 minute receiver sampling time, different concentrations of losartan or PD 123,319 were 
added to the donor chamber.  Receiver samples were then taken for an additional 60 minutes.  
After each receiver sample, the volume was replaced with fresh medium.  The samples were 
placed in a scintillation vial with 10 ml of scintillation cocktail and assayed by scintillation 
spectrometry.  The flux was determined by plotting pmoles vs. minutes for each sampling 
interval (0-30 minutes and 30-90 minutes).  The apparent permeability coefficient was 
calculated using the equation: 
P = Flux / (A*CDo) 
where flux is the slope of each line, A is the area of the membrane, and CDo is the initial donor 
concentration.  The donor concentration did not change by more than 10 % during the time 
period of these experiments. 
Western blot 
Total cellular extract was prepared using confluent monolayers of BMECs.  The cells were lysed 
with a 45 min incubation in ice-cold phosphate buffer saline containing 3 % sodium dodecyl 
sulfate (SDS) and protease inhibitors (0.1mM leupeptin, 73 µM pepstatin A, and 100 µg/ml 
PMSF).  The cell lysate was then centrifuged at 12,000 g for 15 min and the supernatant 
containing solubilized membrane proteins was stored at -20°C and used for further analysis.  
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Total cell protein was measured by the Micro BCA protein assay (Pierce) using bovine serum 
albumin as a standard.  Cell plasma membranes were prepared using confluent monolayers of 
BMECs.  The cells were removed from the tissue culture plates with a trypsin / EDTA solution.  
The cell suspension was then diluted in 5 volumes of ice-cold 10 mM Tris - HCl, 0.1 mM EDTA, 
pH 7.5 (TE buffer) and homogenized.  The homogenate was passed through a fine-gauge 
syringe needle and then centrifuged at 500 g for 15 minutes to pellet unbroken cells and nuclei, 
leaving a membrane containing supernatant.  The plasma membranes were collected by 
centrifugation at 40,000 g for 60 minutes.  The pellets were washed in 10 volumes of TE buffer 
and re-centrifuged at 40,000 g for 60 minutes.  The pellets were resuspended in TE buffer and 
stored at -70°C (19).  The protein concentration was measured by the Micro BCA protein assay 
(Pierce) using bovine serum albumin as a standard.  Cell proteins were electrophoresed on a 10 
% Tris-Glycine gel (NOVEX, San Diego, CA) and transferred to a PVDF membrane.  
Immunoreactive protein was detected with the AT1 polyclonal antibody using the enhanced 
chemiluminescence method (ECL) as per the manufacturer’s protocol (Amersham, Downers 
Grove, IL).  A positive control peptide (Santa Cruz Biotechnology, Inc.) and a negative control 
(serum albumin) were used to establish and confirm blot conditions. 
Statistical analysis 
The comparison between mean values within each experimental series was performed by one-
way analysis of variance using Dunnett’s test to compare several treatments against a control. 
 
Results 
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The temperature and concentration dependence of the binding and internalization kinetics for 
angiotensin II were described in an earlier report (9).  In this study, the uptake of [3H]-
angiotensin II alone and with different concentrations of losartan is shown in Fig. 1.  When 
coincubated for 30 minutes at 37°C, micromolar concentrations of losartan were observed to 
significantly inhibit the binding and uptake of [3H]-angiotensin II.  In Fig. 2 the effect of PD 
123,319 ditrifluoroacetate on angiotensin II uptake is shown.  When different concentrations of 
PD 123,319 were coincubated with [3H]-angiotensin II for 30 minutes, there was no significant 
change in the amount of angiotensin II taken up by the cells. 
Since the concentrations of losartan required to inhibit angiotensin II binding and 
internalization were higher than expected and that earlier studies suggested a role for P-
glycoprotein in mediating losartan distribution across the BBB (20), we performed rhodamine 
123 uptake studies.  The uptake of rhodamine 123 alone and with angiotensin II,  losartan, PD 
123,319, and cyclosporin A is shown in Fig. 3.  The cells were exposed for one hour with 100 µM 
angiotensin II, 750 µM losartan, 500 µM PD 123,319, or 1 µg/ml cyclosporin A.  After the one 
hour incubation, 5 µM rhodamine 123 was added to each well and the cells were incubated 
another hour.  As shown in Fig. 3, losartan, PD 123,319, and cyclosporin A significantly 
increased the uptake of rhodamine 123 in BMECs, indicating that only the nonpeptide 
antagonists interact with P-glycoprotein. 
The permeation of angiotensin II across BMECs was found to increase linearly over time as 
shown in Fig. 4 at 37°C.  The transport of a pulse of [3H]-angiotensin II was monitored alone for 
30 minutes before addition of the antagonists.  The effect of losartan on angiotensin II 
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transport is shown in Fig. 5 where again, micromolar concentrations of losartan were found to 
significantly decrease the transport of [3H]-angiotensin II.  There was no decrease in angiotensin 
II transport seen with PD 123,319 as shown in Fig. 6. 
Western blot studies, shown in Fig. 7A and 7B, were generated using an AT1 receptor polyclonal 
antibody and show that the AT1 receptor is present in BMECs.  Fig. 7A shows the western 
analysis of total cell lysate and Fig. 7B shows the blot of BMEC membranes compared to total 
cell lysate.  The blots indicated that there was a greater concentration of AT1 receptors in the 
membrane portion of the cells. 
 
Discussion 
 Speth and Harik (5) and Grammas et al. (6) originally described the presence of specific 
angiotensin II binding sites on brain microvessels.  A hypothesis developed that angiotensin 
binding sites in the cerebrovasculature regulated water and ion transport (7,8).  Guillot and 
Audus subsequently described angiotensin II binding sites on primary cultures of bovine BMECs, 
a well-characterized in vitro system representing BBB endothelium.  Scatchard analysis of the 
concentration-dependent binding of angiotensin II to BMECs revealed a single population of 
binding sites with an apparent Kd of 3.1 nM (9).  In addition, angiotensin II was observed to be 
internalized intact by BMECs and apical application of the peptide regulated permeability 
properties of the BMEC monolayers at concentrations similar to the binding site affinity (9,21).  
The latter findings have been recently confirmed by other researchers in human brain 
microvessel endothelial cells (22). 
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 In this study, we have shown that the binding and uptake of angiotensin II by BMECs was 
inhibited by losartan, the AT1 receptor antagonist and not the AT2 antagonist, PD 123,319.  This 
observation was consistent with the presence of a single population of angiotensin II binding 
sites that were described by Guillot and Audus (9).  Therefore, it appears that an AT1 receptor 
mediates clearance of angiotensin II by BMECs.  Although our data includes both binding and 
internalization, the concentrations at which an antagonist was inhibitory were higher than 
expected based on other receptor studies (11) and our observation that specific binding of 
angiotensin II to bovine BMECs could be inhibited by nM concentrations of peptide analogs, 
saralasin and sarathrin (9). 
 Our earlier studies on the uptake and transport of losartan itself indicated that the 
compound was an apparent substrate for P-glycoprotein at submicromolar concentrations (20).  
Therefore, P-glycoprotein may be a competing mechanism for losartan interactions with the 
BMEC membrane.  To determine if the antagonists and angiotensin II were potential substrates 
for P-glycoprotein, the uptake studies were performed with rhodamine 123, a specific substrate 
for the P-glycoprotein efflux pump (23-26).  The uptake of rhodamine 123 alone and with 
pretreatment of the monolayers using angiotensin II, losartan, PD 123,319, or a positive 
control, cyclosporin A (26), suggested that both antagonists were inhibitors of P-glycoprotein.  
Angiotensin II does not affect rhodamine 123 uptake, therefore it appears that the nonpeptide 
antagonists may not be as effective in blocking BMEC uptake and binding due to their added 
affinity for P-glycoprotein.  On the other hand, the micromolar concentrations used here 
remain within the concentration range of losartan antagonist activity across a variety of 
different species, tissue types, and angiotensin II mediated biological functions (27). 
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 Angiotensin II was previously shown to be transported across arterial endothelial cell 
monolayers by a specific, saturable mechanism that could be inhibited by unlabeled peptide.  
Mineo et al. required micromolar concentrations of angiotensin to inhibit arterial endothelial 
cell transport of the radiolabeled angiotensin II (10).  We have observed that angiotensin II 
crosses monolayers of BMECs intact (28,29) at a rate slightly higher than expected based on its 
molecular weight.  The transport was also a saturable process, Km 1.7 nM, and angiotensin II 
transport from the apical to the basolateral side was greater than the reverse direction (28,30).  
In the present study, the differential effects of the two angiotensin II receptor antagonists on 
the passage of the peptide through monolayers of BMECs affirmed the role of an AT1 mediated 
mechanism with losartan inhibiting the transport of angiotensin II. As observed in the uptake 
studies, the AT2 antagonist effect on angiotensin II transport was also absent.  Consistent with 
the uptake studies, micromolar concentrations of losartan were required to inhibit angiotensin 
transport. 
 The AT1 receptor belongs to the class of G-protein-coupled seven-transmembrane receptors 
and is made up of 359 amino acids with an unmodified molecular weight of 41,000 (11).  Using 
western blot analysis we confirmed the expression of the AT1 receptor in BMECs.  Further, we 
demonstrated that the AT1 receptor resides in the membrane portion of BMECs.  The AT1 
receptor is responsible for most of the known biological effects of angiotensin II, including 
those of the central nervous system (11,31).  Therefore, expression in the BMECs was 
consistent with most other angiotensin II mediated functions.  At the time of this study, 
antibodies for the AT2 receptor were not available to potentially rule out expression of this class 
of receptors in BMECs. 
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 In addition to peripheral endothelia (10), other cell types have been shown to internalize 
angiotensin II including adrenocortical cells (32) and vascular smooth muscle cells (33,34).  Our 
results suggest that the presence of the AT1 receptor populations mediating BMEC uptake and 
transport of angiotensin II may serve as a local physiological mechanism for controlling 
angiotensin II distribution in the cerebrovasculature.  This observation appears consistent with 
the local control of the renin-angiotensin systems associated with specific tissues (1-3).  
Alternatively, the AT1 receptors might provide a mechanism that could be exploited for 
facilitating delivery of some substances via chimeric constructs into the central nervous system 
like other endogenous peptides, insulin and transferrin (35,36).  However, like insulin, it is also 
apparent that angiotensin II has significant biological activity at the BBB, regulating the BMEC 
secretion of other vasoeffectors (9,21,22,37) and the permeability properties of the cells (7-9) 
that would preclude its use in chimeric constructs.  The nonpeptide antagonists such as losartan 
could provide alternative targeting ligands in a chimeric construct; unfortunately, losartan 
appears to be a substrate for BMEC efflux mechanisms (20).  Therefore, future works in our 
laboratory will focus on the transport of alternative ligands for the carrier, including 
metabolically stable angiotensin II peptide analogs. 
 In summary, we have shown that the uptake and transport of angiotensin II by BMECs 
appears to be mediated by the AT1 receptor.  These results form a better understanding of the 
regulation of cerebrovascular levels of angiotensin II by the BBB and may lead to possible 
delivery strategies for therapeutic chimeric peptides. 
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